Skip to content

Identifying genetic determinants of outcome in multiple sclerosis

Progression in Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN41688895
Enrollment
10000
Registered
2023-05-04
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

The researchers will undertake array-based genome-wide genotyping in DNA extracted from patients' venous blood or saliva

Sponsors

Cambridge University Hospitals NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. A locally confirmed diagnosis of multiple sclerosis 2. At least one measure of Extended Disability Severity Score (EDSS) 3. Able to give valid informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with Radiologically or Clinically Isolated Syndrome (RIS or CIS) 2. Comorbidities causing significant disability likely to have confounded the reliability of the EDSS 3. Inclusion in the discovery cohort of the recently completed first progression GWAS

Design outcomes

Primary

MeasureTime frame
Disability measured using the Extended Disability Status Scale (EDSS) and age-corrected to generate the Age-Related Multiple Sclerosis Severity (ARMSS) Score. All available measures of the ARMSS will be considered in the analysis as observed at any timepoint in the disease course.

Secondary

MeasureTime frame
TIme to event measures including time to EDSS 6.0 and time to confirmed disability worsening. These variables will be assessed in the sub-group of patients with EDSS measured at multiple timepoints.

Countries

England, United Kingdom

Contacts

Public ContactStephen Sawcer
sjs1016@cam.ac.uk+44 (0)1223 762040

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 4, 2026